ArticleFrontiers in pharmacology2025

Discovery of a selective dual-specificity tyrosine phosphorylation-regulated kinase 1B inhibitor with anti-adipogenic and anti-diabetic activities.

Sein Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.